WellUS Biotech

WellUS Biotech's website currently presents three interconnected legal and compliance risks that undermine your credibility as a GMP-certified, regulated manufacturer. Start by treating your website infrastructure with the same rigor you apply to your facility certification. The most urgent fix is adding a privacy policy and terms of service footer—these documents should explicitly address your role as a contract manufacturer, clarify how you protect client formulation data, define IP ownership in OEM/ODM agreements, and outline your manufacturing service scope. Given your emphasis on compliance throughout the site, the absence of these documents creates a jarring inconsistency that sophisticated B2B buyers will immediately notice. Simultaneously, implement a GDPR-compliant cookie consent banner (tools like Termly or OneTrust are standard in the biotech industry) so that tracking of potential clients from EU regions doesn't expose you to regulatory fines. These three foundational fixes should take 2–3 weeks and will directly address how qualified OEM/ODM prospects evaluate your legal and operational maturity. Next, remediate the four unlabeled interactive elements by auditing your site for any buttons, forms, or expandable sections missing aria-label or aria-describedby attributes. This is a quick accessibility win that reinforces your compliance credentials. Finally, add Open Graph meta tags (og:title, og:description, og:image) to your OEM/ODM Services and product showcase pages. When your clients or prospects share these pages on LinkedIn—the primary channel for B2B biotech partnerships—they'll now display branded previews with your custom product images and service description, significantly improving engagement and professional perception. Prioritize the legal and cookie framework first, then tackle accessibility, then social metadata.